PREVYMIS (Letermovir) $默沙东(MRK)$ $109.84
PDUFA date is expected on September 7, 2023.
网页链接{U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ f...查看全文
里程碑milestone2023-09-03 16:58
$BioLineRx(BLRX)$ PDUFA target action date set for September 9, 2023. NDA accepted, noted November 10, 莫替福肽用于多发性骨髓瘤 (MM) 自体移植的干细胞动员 (SCM) Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)。 网页链接查看全文
美股律师郝俊波2023-01-06 10:39
$BioLineRx(BLRX)$ 【BioLineRx(BLRX)最新证券集体诉讼】
BioLineRx Ltd(NASDAQ: BLRX)因证券欺诈案已经被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述,违反证券法令投资者受损。投资者向法院申请判令被告赔偿因其违法行为导致股价下跌给投资...查看全文
肽研社2022-11-17 11:24
业绩表现
Tonix 2022Q3尚未产生营收,处于亏损状态,净亏损$28.98Mn,研发投入为$22.20Mn。目前,Tonix的鼻内催产素TNX-1900正在开发中,计划于2022Q4启动Ⅱ期临床。
Sesen Bio 2022Q3尚未产生营收,处于亏损状态,净亏损$31.96Mn,研发投入为$29.94Mn。同时,其将与专注开发CAR-M疗法的Ca...查看全文
SeekingBiotech2022-11-10 23:21
BioLineRx (BLRX) Announces FDA Acceptance of NDA for APHEXDA$BioLineRx(BLRX)$查看全文
药研网2022-06-29 11:29
6月28日,以色列一家专注肿瘤学的晚期临床阶段生物制药公司BioLineRx Ltd.宣布,已与劲方医药达成合作协议,通过随机的2b期临床试验推进Motixafortide在胰腺导管腺癌(PDAC)方面的发展。
根据协议条款,劲方医药将全面资助、设计和执行一项随机的2b期临床试验,该试验将在中国招募约200名一线...查看全文
chuminhua2022-06-29 10:15
#授权in# 劲方医药今日宣布与纳斯达克上市公司BioLineRx达成合作开发协议,双方将共同拓展BioLineRx旗下头部产品motixafortide(CXCR4抑制剂)适应症范围。BioLineRx近日已与FDA就motixafortide针对干细胞活化效应,完成新药上市前(pre-NDA)会议沟通。按协议,劲方将独立在中国大陆开展motixafor...查看全文
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-23 AccNo: 0001178913-18-000237 Size: 40 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-23 AccNo: 0001178913-18-000235 Size: 41 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ EFFECT - Notice of Effectiveness Filed: 2018-01-19 AccNo: 9999999995-18-000169 Size: 1 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-19 AccNo: 0001178913-18-000207 Size: 14 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2018-01-19 AccNo: 0001178913-18-000205 Size: 646 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ F-3/A [Amend] - Registration statement by foreign private issuers Filed: 2018-01-19 AccNo: 0001178913-18-000197 Size: 64 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-17 AccNo: 0001178913-18-000172 Size: 44 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-12-28 AccNo: 0001178913-17-003491 Size: 11 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-12-28 AccNo: 0001178913-17-003491 Size: 11 KB 网页链接
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ F-3 - Registration statement by foreign private issuers Filed: 2017-12-28 AccNo: 0001178913-17-003489 Size: 1 MB 网页链接